Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 243

Sort by

Sort Order Select

Journal Articles

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics

Florent Malard, MD PhD, Faezeh Legrand, MD, Jérôme Cornillon, MD, Amandine Le Bourgeois, MD, Jean-Baptiste Mear, MD, Deborah Desmier, MD, Emilie Plantamura, PhD PharmD, Ronald Carter, MD MSc, MPH, Thierry Lamy De La Chapelle, MD PhD, Patrice Chevallier, MD, Denis Guyotat, MD PhD, Didier Blaise, MD PhD, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 1993.

https://doi.org/10.1182/blood-2019-125540

Published: 2019

Journal Articles

Disease Burden in Patients with Glanzmann Thrombasthenia: Perspectives from the Glanzmann Thrombasthenia Patient/Caregiver Questionnaire

Alexander Duncan, MD, Angela Kellum, PharmD, Shilpa Jain, Skye Peltier, Helen Smith, David Cooper, Hossam Saad

Blood (2019) 134 (Supplement_1): 3456.

https://doi.org/10.1182/blood-2019-128408

Published: 2019

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

Plasmablastic Lymphoma in a Community-Based Cancer Center: A 10-Year Analysis of This Rare Disease in a Underserved Urban Area

Vinicius Machado Jorge, MD, Andrew Tiu, MD, Sorab Gupta, MD, Claudia Dourado, MD, Gabor Varadi, MD

Blood (2019) 134 (Supplement_1): 5361.

https://doi.org/10.1182/blood-2019-131905

Published: 2019

Journal Articles

Metastatic Lymphoepithelioma-like Carcinoma Treated with PD1-Antibody:Is Epstein-Barr Virus Eradication the Main Mechanism in 2 Refractory Cases in Children?

Haixia Guo, MD PhD, Xuedong Wu, MD PhD, Na LI, Jian LI

Blood (2019) 134 (Supplement_1): 5615.

https://doi.org/10.1182/blood-2019-129871

Published: 2019

Journal Articles

Lower c-D-Index in Acute Myeloid Leukemia with Febrile Neutropenia during Chemotherapy

Tomoya Ishida, MD, Hiroyuki Kubo, MD, Osamu Imataki, MD PhD, Makiko Uemura, MD, Norimitsu Kadowaki, MD PhD

Blood (2019) 134 (Supplement_1): 5190.

https://doi.org/10.1182/blood-2019-126721

Published: 2019

Journal Articles

Probably Pathogenic KMT2D Variants Presenting with Cytopenias and Primary Immune Deficiency

Sun Young Kim, MD PhD, Alexander Ing, MS, CGC, Kristin Clemenz, MS, CGC, Kai Lee Yap, PhD, Sherif M. Badawy, MD, Robert I Liem, MD MS, Alexis A. Thompson, MD MPH, A. Kyle Mack, MD

Blood (2019) 134 (Supplement_1): 2334.

https://doi.org/10.1182/blood-2019-131468

Published: 2019

Journal Articles

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

Cole Sterling, MD, Nina D. Wagner-Johnston, MD, Douglas E Gladstone, MD, Richard F. Ambinder, MD, Lode J. Swinnen, MB ChB, Philip Hollingsworth Imus, MD

Blood (2019) 134 (Supplement_1): 3342.

https://doi.org/10.1182/blood-2019-126253

Published: 2019

Journal Articles

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Yanping Ji, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Guangyu Sun, Jian Wang, Zimin Sun

Blood (2019) 134 (Supplement_1): 5677.

https://doi.org/10.1182/blood-2019-130138

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation

K. Scott Baker, Wendy M. Leisenring, Pamela J. Goodman, Ralph P. Ermoian, Mary E. Flowers, G. Schoch, Rainer Storb, Brenda M. Sandmaier, H. Joachim Deeg

Blood (2019) 133 (26): 2790–2799.

https://doi.org/10.1182/blood.2018874115

Published: 2019

Includes: Supplemental data

Journal Articles

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Francesco Iuliano, MD, Eleonora Iuliano, MD, Marco Rossi, MD

Blood (2018) 132 (Supplement 1): 2449.

https://doi.org/10.1182/blood-2018-99-118518

Published: 2018

Journal Articles

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Zhao Liang, MD PhD, Lei Wang, MD PhD, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2018-99-117694

Published: 2018

Journal Articles

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Leighton Edward Clancy, PhD, Elissa Atkins, GIllian Huang, David Collins, David Bishop, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2018-99-117417

Published: 2018

Journal Articles

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Madan Jagasia, MD MS, Amandeep Salhotra, MD, Carlos R. Bachier, MD, James Essell, MD, Daniel J. Weisdorf, MD, Behyar Zoghi, MD PhD, Laurie S. Green, MD, Olivier Schueller, PhD, Alexandra Zanin-Zhorov, PhD, Jonathan M. Weiss, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 602.

https://doi.org/10.1182/blood-2018-99-111896

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Variability in Bleeding Phenotype in Type 3 VWD Families

Pamela A Christopherson, Veronica H Flood, MD, Sandra L Haberichter, PhD, Joan Cox Gill, MD, Robert R Montgomery, MD, Zimmerman Program Investigators

Blood (2018) 132 (Supplement 1): 2466.

https://doi.org/10.1182/blood-2018-99-112961

Published: 2018

Journal Articles

Burden and Outcomes of Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections (MBI-LCBI) in the First 100 Days after Allogeneic Stem Cell Transplant: A CIBMTR Analysis

Christopher E Dandoy, MD MS, Min Chen, MS, Soyoung Kim, Krishna Komanduri, MD, Caroline A. Lindemans, MD, Miguel-Angel Perales, MD, Marcie L. Riches, MDMS

Blood (2018) 132 (Supplement 1): 3375.

https://doi.org/10.1182/blood-2018-99-114629

Published: 2018

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?

Osman Ilhan, MD, Guldane Cengiz Seval, Zubeyde Nur Ozkurt, Ali Ugur Ural, MD, Meltem Ayli, Omur Gokmen Sevindik, MD, Sinem Civriz Bozdag, MD, Meltem Kurt Yuksel, MD, Zafer Gulbas, MD, Muhit Özcan

Blood (2018) 132 (Supplement 1): 5729.

https://doi.org/10.1182/blood-2018-99-112339

Published: 2018

NARROW

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics

Disease Burden in Patients with Glanzmann Thrombasthenia: Perspectives from the Glanzmann Thrombasthenia Patient/Caregiver Questionnaire

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

Plasmablastic Lymphoma in a Community-Based Cancer Center: A 10-Year Analysis of This Rare Disease in a Underserved Urban Area

Metastatic Lymphoepithelioma-like Carcinoma Treated with PD1-Antibody:Is Epstein-Barr Virus Eradication the Main Mechanism in 2 Refractory Cases in Children?

Lower c-D-Index in Acute Myeloid Leukemia with Febrile Neutropenia during Chemotherapy

Probably Pathogenic KMT2D Variants Presenting with Cytopenias and Primary Immune Deficiency

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Variability in Bleeding Phenotype in Type 3 VWD Families

Burden and Outcomes of Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections (MBI-LCBI) in the First 100 Days after Allogeneic Stem Cell Transplant: A CIBMTR Analysis

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only